These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23282066)

  • 1. Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam.
    Kuze J; Mutoh T; Takenaka T; Oda N; Hanioka N; Narimatsu S
    Xenobiotica; 2013 Jul; 43(7):598-606. PubMed ID: 23282066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
    Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Chen G; Weemhoff JL; Jen C; Kelley CJ; LeDuc BW; Zinny MA
    Clin Pharmacol Ther; 2003 Aug; 74(2):121-9. PubMed ID: 12891222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice.
    Farkas D; Oleson LE; Zhao Y; Harmatz JS; Zinny MA; Court MH; Greenblatt DJ
    J Clin Pharmacol; 2007 Mar; 47(3):286-94. PubMed ID: 17322140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys.
    Ogasawara A; Kume T; Kazama E
    Drug Metab Dispos; 2007 Mar; 35(3):410-8. PubMed ID: 17142564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Separate evaluation of intestinal and hepatic metabolism of three benzodiazepines in rats with cannulated portal and jugular veins: comparison with the profile in non-cannulated mice.
    Kuze J; Mutoh T; Takenaka T; Morisaki K; Nakura H; Hanioka N; Narimatsu S
    Xenobiotica; 2009 Nov; 39(11):871-80. PubMed ID: 19845438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes.
    Perloff MD; von Moltke LL; Cotreau MM; Greenblatt DJ
    Biochem Pharmacol; 1999 Jun; 57(11):1227-32. PubMed ID: 10230766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UPLC-MS/MS analysis of the Michaelis-Menten kinetics of CYP3A-mediated midazolam 1'- and 4-hydroxylation in rat brain microsomes.
    Venkatapura Chandrashekar D; DuBois B; Mehvar R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Aug; 1180():122892. PubMed ID: 34388602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats.
    Lai L; Hao H; Wang Q; Zheng C; Zhou F; Liu Y; Wang Y; Yu G; Kang A; Peng Y; Wang G; Chen X
    Drug Metab Dispos; 2009 Dec; 37(12):2399-407. PubMed ID: 19741040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes.
    Warrington JS; Poku JW; von Moltke LL; Shader RI; Harmatz JS; Greenblatt DJ
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1024-31. PubMed ID: 10688619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory Effect of Oxethazaine on Midazolam Metabolism in Rats.
    Namba H; Nishimura Y; Kurata N; Iwase M; Hirai T; Kiuchi Y
    Biol Pharm Bull; 2017; 40(9):1361-1365. PubMed ID: 28867721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
    van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
    Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir.
    Culm-Merdek KE; von Moltke LL; Gan L; Horan KA; Reynolds R; Harmatz JS; Court MH; Greenblatt DJ
    Clin Pharmacol Ther; 2006 Mar; 79(3):243-54. PubMed ID: 16513448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression.
    Perloff MD; Von Moltke LL; Greenblatt DJ
    Xenobiotica; 2003 Apr; 33(4):365-77. PubMed ID: 12745872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid and simultaneous measurement of midazolam, 1'-hydroxymidazolam and digoxin by liquid chromatography/tandem mass spectrometry: application to an in vivo study to simultaneously measure P-glycoprotein and cytochrome P450 3A activity.
    Xue X; Huang M; Xiao H; Qin X; Huang L; Zhong G; Bi H
    J Pharm Biomed Anal; 2011 Apr; 55(1):187-93. PubMed ID: 21316177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model.
    Cummins CL; Salphati L; Reid MJ; Benet LZ
    J Pharmacol Exp Ther; 2003 Apr; 305(1):306-14. PubMed ID: 12649383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of continuous ingestion of Schisandrin A on CYP3A in the rat.
    Li WL; Xin HW; Su MW
    Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):187-92. PubMed ID: 21895978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.